Drug intelligence / Profile preview

GSK2340273A

Development stage: Phase 3
Lead developer: GSK
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

GSK2340273A is an H1N1 pandemic influenza vaccine developed by GSK. It is an A/California/7/2009 (H1N1)v-like vaccine that was studied for its safety, immunogenicity, and efficacy in various clinical trials. The vaccine was developed in response to the H1N1 influenza pandemic.

Other names: A/California/7/2009 (H1N1)v-like vaccine

Beyond the preview

Go deeper on GSK2340273A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GSK2340273A.

Explore the full profile